The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of NAFLD, is associated with a loss of insulin sensitivity, it is not clear which cellular abnormality arises first. We have explored this in mice overexpressing carbohydrate responsive element-binding protein (ChREBP). On a standard diet, mice overexpressing ChREBP remained insulin sensitive, despite increased expression of genes involved in lipogenesis/fatty acid esterification and resultant hepatic steatosis (simple fatty liver). Lipidomic analysis revealed that the steatosis was associated with increased accumulation of monounsaturated fatty acids (MUFAs). In primary cultures of mouse hepatocytes, ChREBP overexpression induced expression of stearoyl-CoA desaturase 1 (Scd1), the enzyme responsible for the conversion of saturated fatty acids (SFAs) into MUFAs. SFA impairment of insulin-responsive Akt phosphorylation was therefore rescued by the elevation of Scd1 levels upon ChREBP overexpression, whereas pharmacological or shRNA-mediated reduction of Scd1 activity decreased the beneficial effect of ChREBP on Akt phosphorylation. Importantly, ChREBP-overexpressing mice fed a high-fat diet showed normal insulin levels and improved insulin signaling and glucose tolerance compared with controls, despite having greater hepatic steatosis. Finally, ChREBP expression in liver biopsies from patients with nonalcoholic steatohepatitis was increased when steatosis was greater than 50% and decreased in the presence of severe insulin resistance. Together, these results demonstrate that increased ChREBP can dissociate hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In this regard, ChREBP expression in liver biopsies from patients with MASH was observed to be two-fold higher when the histologic steatosis score was greater than 50% compared to those with less than 50%.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“However, it decreased in the presence of severe IR [34,94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Taken together, these findings demonstrate that ChREBP-driven hepatic steatosis can be dissociated from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“genes was achieved by the ΔΔCt method (88).”
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“(91): 0, absent; 1, <5%; 2, 5%–33%; 3, 33%–66%; 4, >66%.”
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296 · cited 1×
“UPR induces transcription of a set of genes whose protein products increase the capacity for protein folding and ER-associated degradation and induces apoptosis when the ER function is severely impaired (41, 42).”
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 11×
“To our knowledge, our work is the first to report that hepatic ChREBP expression varies positively according to the degree of steatosis and inversely to insulin resistance in a cohort of patients with NASH.”
InfluentialDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“Using a multiple-stable-isotope approach, Don-nelly et al. (16) estimated that, of the TG content accounted for in the livers of patients with NAFLD, 60% arose from NEFA, a little over 10% came from the diet, and close to 30% came from de novo lipogenesis, underlying the importance of de novo TG synthesis in the etiol…”
InfluentialNutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075 · cited 17×
“Recent studies have revealed that chronic SFA exposure activates unfolded protein response (UPR) in cultured cells (39, 40).”
InfluentialPGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624 · cited 1×
“In the liver, SIRT1 controls gluconeogenic activity by modulating the acetylation levels of a network of transcription factors and/or coactivators, including PPARGC1A (74–76).”
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · cited 1×
“We also measured the expression of fibroblast growth factor 21 (FGF21), a key metabolic regulator whose expression is regulated via PPAR pathways during states requiring increased fatty acid oxidation (33).”
Research works printed but not linked: 2
- Denechaud, 2008, J Clin Invest., 118, 956
- Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes . 2006;55(8):2159-2170. · DOI · Paper page
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
“Yet the ChREBP-overexpressing mice had normal glucose and insulin tolerance on regular chow diet and were even protected from HFD-induced defects in glucose tolerance and hepatic insulin signaling (49).”
BackgroundEnergy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
“Conversely, overexpression of ChREBP in the liver causes hepatic steatosis without concomitant insulin resistance (13).”
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
“High ChREBP expression was found in biopsies from NASH patients, but levels declined in patients with severe insulin resistance, indicating that ChREBP may segregate hepatic steatosis from insulin resistance [52].”
BackgroundInfluentialThe role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014) · Nature · doi:10.1038/nature13478 · Cited by 1,136
Triglyceride Metabolism in the Liver
Alves‐Bezerra, M., & Cohen, D. E. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170012 · Cited by 1,016
“Expression of both transcriptional factors are upregulated in livers of mouse models of NAFLD (19), however only SREBP-1c is upregulated in patients with NAFLD (115).”
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
“While ChREBP deficiency improves IR and hepatic steatosis by inhibiting the entire lipogenic and esterification process.(328,329) Thus, inhibition of DNL and related pathway may effectively alleviate MAFLD and IR.”
BackgroundDiscovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects
Yore, M. M., Syed, I., Moraes-Vieira, P. M., Zhang, T., Herman, M. A., Homan, E. A., Patel, R. T., Lee, J., Chen, S., Peroni, O. D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.035 · Cited by 842
“Similarly, an increased ratio of monounsaturated to saturated fatty acids in the liver is associated with insulin sensitivity even with extensive hepatic steatosis (Benhamed et al., 2012).”
BackgroundInsulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771
“Hepatic expression of SREBP-1c, ChREBP and other genes involved in lipogenesis are increased in people with hepatic steatosis compared with those who have normal IHTG content (40-44).”
BackgroundIntestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
“Gut-derived bacterial endotoxin LPS is carried to the liver, where it can activate TLR4 and induce the expression of proinflammatory cytokine genes such as Tnfa and Il6 via activation of the transcription factor NF-kB (33).”
Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M., & Gafter, U. (2014) · Journal of Lipid Research · doi:10.1194/jlr.p040501 · Cited by 645
Transcriptional regulation of hepatic lipogenesis
Wang, Y., Viscarra, J., Kim, S.-J., & Sul, H. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4074 · Cited by 646
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 624
Fructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561
“However, whether steatosis itself can cause hepatic insulin resistance remains controversial (131, 161).”
BackgroundModulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
“Furthermore, patients with NASH and SIR had lower levels of ChREBP on liver biopsy.(10) These apparently contradictory effects may be because this transcription factor is important in modulating both glycolysis and lipogenesis, and its predominant effect depends on the degree of steatosis in the surrounding environmen…”
BackgroundErtunc, M. E., & Hotamisligil, G. S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066514 · Cited by 488
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Unraveling the Regulation of Hepatic Metabolism by Insulin
Titchenell, P. M., Lazar, M. A., & Birnbaum, M. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.03.003 · Cited by 437
“Hepatic overexpression of ChREBP is sufficient to induce fatty liver in mice and increased ChREBP has been correlated with NAFLD in humans [27].”
BackgroundRegulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues
Song, Z., Xiaoli, A. M., & Yang, F. (2018) · Nutrients · doi:10.3390/nu10101383 · Cited by 435
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
The ménage à trois of autophagy, lipid droplets and liver disease
Filali-Mouncef, Y., Hunter, C., Roccio, F., Zagkou, S., Dupont, N., Primard, C., Proikas-Cezanne, T., & Reggiori, F. (2022) · Autophagy · doi:10.1080/15548627.2021.1895658 · Cited by 361
“Conversely, MLXIPL overexpression in HFD fed mice caused increased DNL and hepatic TAG accumulation, while also displaying normal insulin levels and insulin signaling [180].”
BackgroundAzzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Softic, S., Gupta, M. K., Wang, G.-X., Fujisaka, S., O’Neill, B. T., Rao, T. N., Willoughby, J., Harbison, C., Fitzgerald, K., Ilkayeva, O., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94585 · Cited by 347
Resolving the paradox of hepatic insulin resistance
Santoleri, D., & Titchenell, P. M. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.016 · Cited by 336
“cient to increase fatty liver progression because overexpression of hepatic ChREBP in mice results in steatosis.(49) Consistent with these mouse studies, obese human beings typically have higher ChREBP expression in the liver, which correlates with fatty liver.”
BackgroundMolecular mechanisms of hepatic apoptosis
Wang, K. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.499 · Cited by 329
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
“ChREBP stimulates the expression of glycolytic genes, augmenting substrate availability for DNL, and induces the expression of stearoyl-CoA desaturase 1 (SCD1), the enzyme responsible for the conversion of saturated to monounsaturated FA, increasing TAG accumulation [111].”
BackgroundTranscriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP
Xu, X., So, J.-S., Park, J.-G., & Lee, A.-H. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358523 · Cited by 308
“111 Carbohydrate response element binding protein expression is induced during adipocyte differentiation, and by refeeding with a high-carbohydrate diet in adipose tissue, suggesting it might have a metabolic function in adipocytes.”
De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health
Eissing, L., Scherer, T., Tödter, K., Knippschild, U., Greve, J. W., Buurman, W. A., Pinnschmidt, H. O., Rensen, S. S., Wolf, A. M., Bartelt, A., et al. (2013) · Nature Communications · doi:10.1038/ncomms2537 · Cited by 301
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Fructose and hepatic insulin resistance
Softic, S., Stanhope, K. L., Boucher, J., Divanovic, S., Lanaspa, M. A., Johnson, R. J., & Kahn, C. R. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1711360 · Cited by 251
“results in hepatic steatosis, but hepatic steatosis in this context is dissociated from development of insulin resistance and metabolic complications [41].”
BackgroundStearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer
Tracz-Gaszewska, Z., & Dobrzyn, P. (2019) · Cancers · doi:10.3390/cancers11070948 · Cited by 248
“Sterol regulatory element binding protein 1 (SREBP1) and carbohydrate response element binding protein (ChREBP) are the main drivers of these pathways, respectively.”
BackgroundInfluentialFructose ingestion acutely stimulates circulating FGF21 levels in humans
Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.008 · Cited by 233
Sweet Sixteenth for ChREBP: Established Roles and Future Goals
Abdul-Wahed, A., Guilmeau, S., & Postic, C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.004 · Cited by 231
“Although other reports also suggest direct promoter binding as a mechanism for ChREBPmediated gene repression (Boergesen et al., 2011; Noordeen et al., 2010), this mechanism should be regarded with caution as it has been recently challenged (Schmidt et al., 2016).”
BackgroundSelf-citationGirousse, A., Tavernier, G., Valle, C., Moro, C., Mejhert, N., Dinel, A.-L., Houssier, M., Roussel, B., Besse-Patin, A., Combes, M., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001485 · Cited by 221
“important part in the favourable metabolic profile [35,37,38].”
BackgroundChREBP regulates fructose-induced glucose production independently of insulin signaling
Kim, M.-S., Krawczyk, S. A., Doridot, L., Fowler, A. J., Wang, J. X., Trauger, S. A., Noh, H.-L., Kang, H. J., Meissen, J. K., Blatnik, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81993 · Cited by 212
“Nuclear translocation of ChREBP-α may be important for CHO-mediated activation (41–43).”
BackgroundNovel insights into ChREBP regulation and function
Filhoulaud, G., Guilmeau, S., Dentin, R., Girard, J., & Postic, C. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.01.003 · Cited by 210
Self-citationZiolkowska, S., Binienda, A., Jabłkowski, M., Szemraj, J., & Czarny, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011128 · Cited by 207
“Liver biopsies from patients with NASH demonstrated increased ChREBP expression, where steatosis was greater than 50% and decreased expression in the presence of severe IR [46].”
BackgroundParlati, L., Régnier, M., Guillou, H., & Postic, C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100346 · Cited by 167
“hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.(65) More recently, Bricambert et al.”
BackgroundInfluentialSelf-citationPathophysiology of lipid droplet proteins in liver diseases
Carr, R. M., & Ahima, R. S. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.10.021 · Cited by 179
Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism
Tang, Y., Wallace, M., Sanchez-Gurmaches, J., Hsiao, W.-Y., Li, H., Lee, P. L., Vernia, S., Metallo, C. M., & Guertin, D. A. (2016) · Nature Communications · doi:10.1038/ncomms11365 · Cited by 171
“This is consistent with high ChREBP expression in the liver increases hepatic lipogenic gene expression and steatosis without impairing insulin sensitivity 29 .”
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis
Lee, J. J., Lambert, J. E., Hovhannisyan, Y., Ramos-Roman, M. A., Trombold, J. R., Wagner, D. A., & Parks, E. J. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.092262 · Cited by 164
Liu, B., Jiang, S., Li, M., Xiong, X., Zhu, M., Li, D., Zhao, L., Qian, L., Zhai, L., Li, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07185-y · Cited by 163
ter Horst, K. W., Gilijamse, P. W., Versteeg, R. I., Ackermans, M. T., Nederveen, A. J., la Fleur, S. E., Romijn, J. A., Nieuwdorp, M., Zhang, D., Samuel, V. T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.035 · Cited by 162
“There are also circumstances, in both animals and humans, in which hepatic insulin resistance is dissociated fromhepatic steatosis (Amaro et al., 2010; Benhamed et al., 2012; Brown et al., 2010; Buettner et al., 2004; Monetti et al., 2007; Semple et al., 2009; Visser et al., 2011).”
Carbohydrate Sensing Through the Transcription Factor ChREBP
Ortega-Prieto, P., & Postic, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00472 · Cited by 162
Self-citationCantley, J. L., Yoshimura, T., Camporez, J. P. G., Zhang, D., Jornayvaz, F. R., Kumashiro, N., Guebre-Egziabher, F., Jurczak, M. J., Kahn, M., Guigni, B. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219456110 · Cited by 161
Glucose-6 Phosphate, a Central Hub for Liver Carbohydrate Metabolism
Rajas, F., Gautier‐Stein, A., & Mithieux, G. (2019) · Metabolites · doi:10.3390/metabo9120282 · Cited by 173
“On the contrary, the overexpression of ChREBP led to the development of hepatic steatosis without concomitant insulin resistance [27].”
BackgroundMetabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
“In line, ChREBP overexpression induced stearoyl-CoA desaturase 1 (Scd1) expression, an enzyme responsible for the biosynthesis of monounsaturated fatty acids (MUFA), resulting in increased liver fat content [44].”
Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
Gruben, N., Shiri‐Sverdlov, R., Koonen, D. P. Y., & Hofker, M. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.08.004 · Cited by 169
“Another explanation may be the enrichment of beneficial lipid species (mono-unsaturated fatty acids, MUFAs) and the reduction of detrimental lipid species (SFAs) found in mice overexpressing Chrebp in the liver [46].”
BackgroundInfluentialIizuka, K., Takao, K., & Yabe, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587189 · Cited by 175
“hepatic Chrebp overexpression reduces the concentrations of saturated fatty acids (SFAs), such as palmitic acid (C16:0) and stearic acid (C18:0); and increases that of the MUFA oleic acid (C18:1 n-9) (32, 57).”
BackgroundHepatic glucose sensing is required to preserve β cell glucose competence
Seyer, P., Vallois, D., Poitry-Yamate, C., Schütz, F., Metref, S., Tarussio, D., Maechler, P., Staels, B., Lanz, B., Grueter, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65538 · Cited by 148
“In contrast to what might have been expected from ChREBP overexpression (24), there was no steatosis in the liver of LG2KO mice, and VLDL secretion was only moderately increased.”
BackgroundPleiotropic genes for metabolic syndrome and inflammation
Kraja, A. T., Chasman, D. I., North, K. E., Reiner, A. P., Yanek, L. R., Kilpeläinen, T. O., Smith, J. A., Dehghan, A., Dupuis, J., Johnson, A. D., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.04.007 · Cited by 146
“Deletions of the four above contiguous genes have been identified as causing a Williams-Beuren syndrome, a multisystem developmental disorder, where 75% of cases show severe GLUC intolerance [66].”
BackgroundLipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 181
Vijayakumar, A., Aryal, P., Wen, J., Syed, I., Vazirani, R. P., Moraes-Vieira, P. M., Camporez, J. P., Gallop, M. R., Perry, R. J., Peroni, O. D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.091 · Cited by 143
“A metabolic signature of increased fatty acid desaturation (monounsaturated to saturated fatty acid ratio) and elongation is associated with insulin sensitivity in humans and rodents (Benhamed et al., 2012; Rhee et al., 2011).”
BackgroundPetrescu, M. D., Vlaicu, S. I., Ciumărnean, L., Milaciu, M. V., Mărginean, C., Florea, M., Vesa, Ș. C., & Popa, M. (2022) · Medicina · doi:10.3390/medicina58050641 · Cited by 174
E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis
Denechaud, P.-D., Lopez-Mejia, I. C., Giralt, A., Lai, Q., Blanchet, E., Delacuisine, B., Nicolay, B. N., Dyson, N. J., Bonner, C., Pattou, F., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81542 · Cited by 141
“Conversely, insulin sensitization does not require amelioration of liver steatosis, as shown in CHREBPoverexpressing mice fed a high-fat diet, which were protected against insulin resistance despite increased lipid accumulation in the liver (28).”
BackgroundMethodInfluentialSelf-citationRoumans, K. H. M., Lindeboom, L., Veeraiah, P., Remie, C. M. E., Phielix, E., Havekes, B., Bruls, Y. M. H., Brouwers, M. C. G. J., Ståhlman, M., Alssema, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15684-0 · Cited by 138
Dissociating fatty liver and diabetes
Sun, Z., & Lazar, M. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.09.005 · Cited by 136
Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome
Cooke, A. A., Connaughton, R. M., Lyons, C. L., McMorrow, A. M., & Roche, H. M. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.021 · Cited by 152
The Role of Dietary Sugars and De novo Lipogenesis in Non-Alcoholic Fatty Liver Disease
Moore, J., Gunn, P., & Fielding, B. (2014) · Nutrients · doi:10.3390/nu6125679 · Cited by 133
“Importantly, ChREBP, SREBP-1c and LXR have all been shown to be expressed at higher levels in NAFLD patients [63–66].”
BackgroundPeriostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα
Lu, Y., Liu, X., Jiao, Y., Xiong, X., Wang, E., Wang, X., Zhang, Z., Zhang, H., Pan, L., Guan, Y., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74438 · Cited by 131
“PPARα (encoded by Ppara), a master regulator of mitochondrial and peroxisomal fatty acid oxidation critical role in the induction of glucose-regulated genes in the liver (17, 18).”
Duval, C., Teixeira-Clerc, F., Leblanc, A. F., Touch, S., Emond, C., Guerre-Millo, M., Lotersztajn, S., Barouki, R., Aggerbeck, Μ., & Coumoul, X. (2016) · Environmental Health Perspectives · doi:10.1289/ehp316 · Cited by 151
Ran, H., Zhu, Y., Deng, R., Zhang, Q., Liu, X., Feng, M., Zhong, J., Lin, S., Tong, X., & Su, Q. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0711-9 · Cited by 140
“As one of the target genes of ChREBP, a glucose sensing transcription factor, SCD1 plays an important role in T2DM [51].”
BackgroundInfluentialA Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response
Iroz, A., Montagner, A., Benhamed, F., Levavasseur, F., Polizzi, A., Anthony, E., Régnier, M., Fouché, E., Lukowicz, C., Cauzac, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.065 · Cited by 128
“This result is consistent with a previous study in which hepatic ChREBP overexpression improved impaired glucose tolerance of high-fat-diet-challenged mice (Benhamed et al., 2012) and is in agreement with a recent study reporting that liver Chrebp knockout mice exhibit impaired insulin sensitivity and glucose intolera…”
ResultSelf-citationCirculating FGF21 in humans is potently induced by short term overfeeding of carbohydrates
Lundsgaard, A.-M., Fritzen, A. M., Sjøberg, K. A., Myrmel, L. S., Madsen, L., Wojtaszewski, J. F. P., Richter, E. A., & Kiens, B. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.001 · Cited by 126
Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations
Wong, R. J., & Ahmed, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i5.263 · Cited by 139
Mejhert, N., Kuruvilla, L., Gabriel, K. R., Elliott, S. D., Guie, M.-A., Wang, H., Lai, Z. W., Lane, E. A., Christiano, R., Danial, N. N., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.014 · Cited by 121
“In contrast, MLX and MLXIPL are predominantly expressed in white adipose tissue and liver where they control the transcription of enzymes regulating de novo lipogenesis (Benhamed et al., 2012; Dentin et al., 2006; Herman et al., 2012; Iizuka et al., 2004; Vijayakumar et al., 2017).”
BackgroundInfluence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
Ghetti, F. D. F., de Oliveira, D. G., de Oliveira, J. M., Ferreira, L. E. V. V. D. C., Cesar, D. E., & Moreira, A. P. B. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1524-x · Cited by 130
“The monosaccharides produced by microbial fermentation are absorbed and transferred to the liver through portal circulation, where they activate factors like the carbohydrate-responsive element-binding protein (ChREBP), which increases the transcription of proteins involved in hepatic lipogenesis [72].”
BackgroundRecent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes
Sahini, N., & Borlak, J. T. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.02.002 · Cited by 129
Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside
Gariani, K., Philippe, J., & Jornayvaz, F. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.11.002 · Cited by 113
“[78] Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M,”
BackgroundFructose, but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues
Baena, M., Sangüesa, G., Dávalos, A., Latasa, M.-J., Sala‐Vila, A., Sánchez, R. M., Roglans, N., Laguna, J. C., & Alegret, M. (2016) · Scientific Reports · doi:10.1038/srep26149 · Cited by 118
Ding, C., Zhao, Y., Shi, X., Zhang, N., Zu, G., Li, Z., Zhou, J., Gao, D., Lv, L., Tian, X., et al. (2016) · Scientific Reports · doi:10.1038/srep28734 · Cited by 113
“Moreover, some phenolic compounds have been reported to confer protective effects against NAFLD by targeting this pathway 8,19,41,47 .”
Metabolic Changes of Hepatocytes in NAFLD
Lu, Q., Tian, X., Wu, H., Huang, J., Li, M., Mei, Z., Zhou, L., Xie, H., & Zheng, S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.710420 · Cited by 127
Caputo, T., Gilardi, F., & Desvergne, B. (2017) · FEBS Letters · doi:10.1002/1873-3468.12742 · Cited by 124
Mondo-Mlx Mediates Organismal Sugar Sensing through the Gli-Similar Transcription Factor Sugarbabe
Mattila, J., Havula, E., Suominen, E., Teesalu, M., Surakka, I. L., Hynynen, R., Kilpinen, H., Väänänen, J., Hovatta, I., Käkelä, R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.081 · Cited by 115
“Previous studies on mouse and Drosophila mutants have established the conservation and physiological importance of ChREBP/Mondo-Mlx (Havula et al., 2013; Iizuka et al., 2004).”
BackgroundInfluentialYang, Y., Li, W., Li, Y., Wang, Q., Gao, L., & Zhao, J. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/145641 · Cited by 108
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 107
Zhang, D., Tong, X., VanDommelen, K., Gupta, N., Stamper, K., Brady, G. F., Meng, Z., Lin, J., Rui, L., Omary, M. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89934 · Cited by 107
Malaisé, Y., Menard, S., Cartier, C., Gaultier, E., Lasserre, F., Lencina, C., Harkat, C., Geoffre, N., Lakhal, L., Castan, I., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15196-w · Cited by 107
Glucose Transporter 8 (GLUT8) Mediates Fructose-induced de Novo Lipogenesis and Macrosteatosis
DeBosch, B. J., Chen, Z., Saben, J. L., Finck, B. N., & Moley, K. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.527002 · Cited by 105
“This finding is not without precedent; hepatic carbohydrate response element binding protein overexpression increased high-fat diet-induced hepatic steatosis while reducing circulating FFA levels, fasting insulin and glucose when compared with WT controls (33).”
The role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
Self-citationKursawe, R., Caprio, S., Giannini, C., Narayan, D., Lin, A., D’Adamo, E., Shaw, M., Pierpont, B., Cushman, S. W., & Shulman, G. I. (2013) · Diabetes · doi:10.2337/db12-0889 · Cited by 99
“(21), showing a negative correlation of ChREBP expression and HOMA-IR.”
Hepatic glucose sensing and integrative pathways in the liver
Oosterveer, M. H., & Schoonjans, K. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1505-z · Cited by 114
“This finding indicates that under conditions of dietary fat overload, ChReBPmediated lipogenesis likely contributes to a metabolically benign state by promoting mono-unsaturated fatty acid synthesis [154, 157].”
BackgroundBricambert, J., Alves‐Guerra, M., Estèves, P., Prip‐Buus, C., Bertrand‐Michel, J., Guillou, H., Chang, C. J., Wal, M. N. V., Canonne‐Hergaux, F., Mathurin, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04361-y · Cited by 117
Self-citationThe role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects
Ren, L., Cui, H., Wang, Y., Ju, F., Cai, Y., Gang, X., & Wang, G. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114465 · Cited by 110
Pathway-selective Insulin Resistance and Metabolic Disease: The Importance of Nutrient Flux
Otero, Y. F., Stafford, J. M., & McGuinness, O. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.576355 · Cited by 94
“In humans, ChREBP expression is positively correlated with hepatosteatosis, but negatively related with insulin resistance (99).”
BackgroundFood components with antifibrotic activity and implications in prevention of liver disease
Bae, M., Park, Y., & Lee, J. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.11.003 · Cited by 101
Intestinal, but not hepatic, ChREBP is required for fructose tolerance
Kim, M., Astapova, I. I., Flier, S. N., Hannou, S. A., Doridot, L., Sargsyan, A., Kou, H. H., Fowler, A. J., Liang, G., & Herman, M. A. (2017) · JCI Insight · doi:10.1172/jci.insight.96703 · Cited by 93
Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.
Liu, H., & Peng, D. (2022) · PubMed Central · doi:10.1530/ec-21-0002 · Cited by 53
“ChREBP also regulates plasma TG levels by regulating FGF21 (74, 75).”
Ding, Z., Pan, Y., Shang, T., Jiang, T., Lin, Y., Yang, C., Pang, S., Cui, X., Wang, Y., Feng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41852-z · Cited by 104
“As ChREBP and LXR α were shown to increase SCD1 transcription in a SREBP-dependent manner 31,32 , we performed chromatin immunoprecipitation (ChIP) analysis with SREBP antibody in HepG2-Ctrl and HepG2-shURI cells and revealed that multiple binding sites of SREBP in the SCD1 promoter regions (Fig.”
Free Fatty Acids and Their Metabolism Affect Function and Survival of Podocytes
Sieber, J., & Jehle, A. W. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00186 · Cited by 94
“Moreover, mice overexpressing chREBP (carbohydrate response element-binding protein) fed a high-fat diet have increased hepatic levels of SCD1 and DGAT1 and show elevated insulin sensitivity despite increased hepatic steatosis (80).”
BackgroundPathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
Akhtar, D. H., Iqbal, U., Vazquez‐Montesino, L. M., Dennis, B. B., & Ahmed, A. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00028 · Cited by 108
“Furthermore, patients with NASH and severe insulin resistance have lower levels of ChREBP on liver biopsy.(67) Additionally, adipocytes can secrete adipocytokines, such as leptin and resistin (inflammatory), and adiponectin (anti-inflammatory), which exert their affects through cytokine signaling pathways.”
BackgroundGut Microbiome‐Induced Shift of Acetate to Butyrate Positively Manages Dysbiosis in High Fat Diet
Si, X., Shang, W., Zhou, Z., Strappe, P., Wang, B., Bird, A. R., & BLANCHARD, C. L. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700670 · Cited by 88
Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., & An, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294267 · Cited by 113
Sphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 95
Self-citationIizuka, K. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.029 · Cited by 91
“In accordance with those data, adenoviral overexpression of ChREBP in the liver results in increased fat accumulation (especially monounsaturated fatty acids) [79].”
BackgroundRole of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD
Fuchs, C. D., Claudel, T., & Trauner, M. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.08.001 · Cited by 91
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
InfluentialLiver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Challa, T. D., Wueest, S., Lucchini, F. C., Dedual, M. A., Modica, S., Borsigova, M., Wolfrum, C., Blüher, M., & Konrad, D. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810124 · Cited by 80
“…uptake of free fatty acids (FFA), elevated de novo lipogenesis, decreased fat oxidation, reduced hepatic very low-density lipoprotein (VLDL) secretion, and impaired autophagy may contribute to the development of hepatic steatosis (Kohjima et al , 2007; Benhamed et al , 2012; Hur et al , 2016).”
The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., & Persico, M. (2021) · Nutrients · doi:10.3390/nu13041314 · Cited by 91
“ChREBP, in addition to the induction of several enzymes required for DNL, suppresses fatty acid oxidation through the downregulation of carnitine palmitoyltransferase 1a, limiting, then, the translocation of fatty acids into the mitochondria [53].”
Background
Metadata
- Authors
- Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Saint-Antoine (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Toxicologie Alimentaire (FR)
- Institut Cochin (FR)
- Corresponding author
- Postic, Catherine
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-06-01
- Volume
- 122
- Issue
- 6
- Pages
- 2176-2194
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3366390
- OpenAlex
- W2117220292
- Cited by
- 408
- References
- 94
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 22 · 2023: 35 · 2022: 27 · 2021: 28 · 2020: 34 · 2019: 23 · 2018: 25 · 2017: 35 · 2016: 27 · 2015: 30 · 2014: 41 · 2013: 27 · 2012: 13
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion)
- Funders
- European Commission
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale (U1016)
- Association Française pour l'Etude du Foie (AFEF-2008)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- ChREBP, carbohydrate-responsive element-binding protein, hepatic steatosis, insulin resistance, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipogenesis, fatty acid esterification, stearoyl-CoA desaturase 1, monounsaturated fatty acids, Akt phosphorylation, insulin signaling, glucose tolerance, high-fat diet, lipidomics, hepatocytes
- MeSH terms
- Animals, Fatty Acids, Monounsaturated, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Nuclear Proteins, Phosphorylation, Stearoyl-CoA Desaturase, Transcription Factors, Metabolic Syndrome, Lipogenesis, Proto-Oncogene Proteins c-akt, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.